Ebos Group (NZSE:EBO) Beta: 0.4030 (As of Jun. 24, 2026)


NZSE:EBO Ebos Group Ltd NZSE:EBO
80 GF Score
Price NZ$20.12
GF Value NZ$40.02
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ebos Group Beta?

Ebos Group NZSE:EBO -0.64% 80 Beta is 0.4030 as of Jun. 24, 2026. GuruFocus rates NZSE:EBO with a GF Score™ of 80/100 and a GF Value™ of NZ$40.02 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Ebos Group's Beta is 0.4030.


Ebos Group  (NZSE:EBO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Ebos Group Beta Related Terms


Ebos Group Beta Historical Data

* Premium members only.

The historical data trend for Ebos Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group Beta Chart

Ebos Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.38 0.52 0.63 0.45

Ebos Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.63 0.54 0.45 0.40

NZSE:EBO vs MCK, COR, CAH: Beta Comparison

For the Medical Distribution subindustry, Ebos Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ebos Group Beta vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Beta distribution charts can be found below:

* The bar in red indicates where Ebos Group's Beta falls into.


NZSE:EBO
80GF Score
Ebos Group Ltd NZSE:EBO
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ebos Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4030 mean?
Ebos Group (NZSE:EBO) has a Beta of 0.4030 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Ebos Group and its competitors.
Is Ebos Group's Beta too high?
Ebos Group's current Beta is 0.4030. Overall, Ebos Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Beta compare to MCK and COR?
Ebos Group's Beta of 0.4030 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Distribution company?
A good Beta depends on the Medical Distribution industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Ebos Group and its competitors. Ebos Group's current Beta is 0.4030. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (NZSE:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is NZ$40.02, compared to a current price of NZ$20.12 — trading 49.7% below its estimated fair value. The current Beta is 0.4030. Ebos Group's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Ebos Group (NZSE:EBO), the current Beta is 0.4030 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (NZSE:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of NZ$20.12 is trading 49.7% below its estimated GF Value™ of NZ$40.02. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for NZSE:EBO:

  • Beta: 0.4030
  • GF Value™: NZ$40.02 vs. price of NZ$20.12 (49.7% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the NZSE:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
80GF Score

Get the complete analysis for NZSE:EBO

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$20.12
Price
NZ$40.02
GF Value